[Leish-l] RES: testing vaccinated dogs for immunopotentiation
Petersen, Christine A [V PTH]
kalicat at iastate.edu
Wed Sep 28 13:23:03 BRT 2011
The reference for this article is: http://www.ncbi.nlm.nih.gov/pubmed/21532741
As it was published in a PLoS journal its free access to all.
Based on our studies and recent ones from Brazil, I do believe that to remove Leish from the canine reservoir, transmission from mom to pup will need to be addressed.
Christy Petersen
From: Chang, Kwang-Poo [mailto:KwangPoo.Chang at rosalindfranklin.edu]
Sent: Wednesday, September 28, 2011 10:20 AM
To: TECSA - Luiz Ristow; John David
Cc: leish-l at lineu.icb.usp.br; Petersen, Christine A [V PTH]
Subject: RE: [Leish-l] RES: testing vaccinated dogs for immunopotentiation
Christine Petersen published an article about transplacental transmission of L infantum in the USA canine leishmaniasis. I just wonder about the implication of this finding in considering vaccination against the disease transmitted this way ?
KP
________________________________
From: leish-l-bounces at lineu.icb.usp.br<mailto:leish-l-bounces at lineu.icb.usp.br> [mailto:leish-l-bounces at lineu.icb.usp.br]<mailto:[mailto:leish-l-bounces at lineu.icb.usp.br]> On Behalf Of TECSA - Luiz Ristow
Sent: Wednesday, September 28, 2011 9:08 AM
To: 'John David'
Cc: leish-l at lineu.icb.usp.br<mailto:leish-l at lineu.icb.usp.br>
Subject: [Leish-l] RES: testing vaccinated dogs for immunopotentiation
Hi !
There are these papers about
These need a very critical reading to discuss
This discussion with all about the matter and these papers is very welcome! (at least for me!)
Regards for all
Luiz Ristow
[cid:image001.gif at 01CC7DD0.FD000BD0]
De: leish-l-bounces at lineu.icb.usp.br<mailto:leish-l-bounces at lineu.icb.usp.br> [mailto:leish-l-bounces at lineu.icb.usp.br]<mailto:[mailto:leish-l-bounces at lineu.icb.usp.br]> Em nome de John David
Enviada em: segunda-feira, 26 de setembro de 2011 18:44
Para: Dr GR Rajasekariah
Cc: leish-l at lineu.icb.usp.br<mailto:leish-l at lineu.icb.usp.br>; Carlos Gouvea; hubert mazure; smithyman at cellabs.com.au<mailto:smithyman at cellabs.com.au>
Assunto: Re: [Leish-l] testing vaccinated dogs for immunopotentiation
I think that for any vaccine developed to protect dogs against VL, but which is also meant to prevent transmission of VL to humans, the developers should show that after the vaccinated dog has been challenged with Leishmania, it does not transmit Leishmania to sand flies.
John R David, M.D.
Richard Pearson Strong Professor Emeritus
Department of Immunology and Infectious Diseases
Harvard School of Public Health
Professor of Medicine, Harvard Medical School
300 W. 23rd Street, Apt. 13K
New York, NY, 10011
Tel: 212 414 8646
Email: jdavid at hsph.harvard.edu<mailto:jdavid at hsph.harvard.edu>
On Sep 19, 2011, at 12:04 AM, Dr GR Rajasekariah wrote:
Hello EveryOne,
I am responding to the topic on European VL Dog vaccine.
It is a great challenge in devising a protective vaccine against visceral leishmaniasis in dogs. This point equally applies the same challenge for human situation.
Because Th-2 response is so dominant during VL infection, modulating Th-2 into Th-1 response is a big challenge to immunologists.
Key points lies in the presentation of appropriate antigen in appropriate dose to stimulate the Th-1 dependent protective immune response.
I understand several vaccines are in the market and real efficacy of these vaccines will come out once introduced to field conditions.
I just wanted to inform you that we have a suitable antibody kit for testing the immunopotentiation in dogs following vaccination of dogs.
Our assay is based on the released promastigote antigens.
It is a highly sensitive assay.
Currently we supply reagents for determination of total IgG antibodies in serum.
If any particular group is interested then we are able to provide appropriate reagent for detection of specific IgG2 and other isotype specific antibody detection.
Because our antibody detection ELISA is based on the exo-antigens such an ELISA would be of exceptional type for measuring antibody response in vaccinated animals.
Highly suitable for diagnosing dogs responded to vaccines.
Recently I came to know that some of commercial kits were found to be not useful for detecting seroconversion in dogs vaccinated with FML vaccine (Leish-Immune) in Brazil.
Because we use released antigens in our kit, any such problems will overcome if they use Canine Leish IgG CELISA (Manufacturer Cellabs Pty Ltd Brookvale NSW Australia email sales at cellabs.com.au<mailto:sales at cellabs.com.au>).
If any one is interested to know more about our antibody detection ELISA based on exo-antigens please contact us.
This is for your kind information.
Dr GR Rajasekariah
Sydney
Australia
raj at cellabs.com.au<mailto:raj at cellabs.com.au>
----- Original Message ----- From: <leish-l-request at lineu.icb.usp.br<mailto:leish-l-request at lineu.icb.usp.br>>
To: <leish-l at lineu.icb.usp.br<mailto:leish-l at lineu.icb.usp.br>>
Sent: Wednesday, August 10, 2011 5:18 PM
Subject: Leish-l Digest, Vol 44, Issue 3
Send Leish-l mailing list submissions to
leish-l at lineu.icb.usp.br<mailto:leish-l at lineu.icb.usp.br>
To subscribe or unsubscribe via the World Wide Web, visit
http://lineu.icb.usp.br/cgi-bin/mailman/listinfo/leish-l
or, via email, send a message with subject or body 'help' to
leish-l-request at lineu.icb.usp.br<mailto:leish-l-request at lineu.icb.usp.br>
You can reach the person managing the list at
leish-l-owner at lineu.icb.usp.br<mailto:leish-l-owner at lineu.icb.usp.br>
When replying, please edit your Subject line so it is more specific
than "Re: Contents of Leish-l digest..."
Today's Topics:
1. European VL Dog Vaccine - CaniLeish?: (jeffrey shaw)
2. Re: FW: Leishmaniasis Pathology Network (Moazzem Hossain)
3. Re: FW: Leishmaniasis Pathology Network (Moazzem Hossain)
----------------------------------------------------------------------
Message: 1
Date: Tue, 9 Aug 2011 15:18:44 +0000
From: jeffrey shaw <jayusp at hotmail.com<mailto:jayusp at hotmail.com>>
Subject: [Leish-l] European VL Dog Vaccine - CaniLeish?:
To: Leish-L <leish-l at lineu.icb.usp.br<mailto:leish-l at lineu.icb.usp.br>>
Message-ID: <COL101-W1CDD4171D44B715B795E9CB200 at phx.gbl<mailto:COL101-W1CDD4171D44B715B795E9CB200 at phx.gbl>>
Content-Type: text/plain; charset="windows-1252"
CaniLeish?:
The European Commission granted a marketing authorisation valid throughout the European Union, for CaniLeish to Virbac S.A. on 14/03/2011.
This vaccine, CaniLeish?, will initially be launched in Portugal at the end of the first half of 2011. This will be followed rapidly by launches in other countries in the endemic area: Spain, France, Greece and Italy (not in chronological order). This roll-out takes account of the geographical prevalence of the disease and the time required to build vaccine production up to full capacity. The launch in Northern European countries from where there is a flow of summer visitors to the endemic area will be part of a second phase.
The basis of this vaccine are excreted proteins plus a saponin adjuvant purified from Quil-A. Its efficacy was determined in a 2 year open field trial.
The vaccine is given to dogs as three injections, three weeks apart, under the skin. The first injection can be given from six months of age, the second injection is given three weeks later and the third three weeks from the second one. Afterward a single ?booster? should be given every year to maintain protection.
-------------- next part --------------
An HTML attachment was scrubbed...
URL: <http://lineu.icb.usp.br/pipermail/leish-l/attachments/20110809/f2404f5e/attachment-0001.htm>
------------------------------
Message: 2
Date: Wed, 10 Aug 2011 13:07:17 +0600
From: Moazzem Hossain <directordcbd at gmail.com<mailto:directordcbd at gmail.com>>
Subject: Re: [Leish-l] FW: Leishmaniasis Pathology Network
To: jeffrey shaw <jayusp at hotmail.com<mailto:jayusp at hotmail.com>>, "Prof. Paul Kaye"
<paul.kaye at york.ac.uk<mailto:paul.kaye at york.ac.uk>>
Cc: "Prof. Dr. Moazzem Hossain" <profdrmoazzemhossain at gmail.com<mailto:profdrmoazzemhossain at gmail.com>>,
Leish-L <leish-l at lineu.icb.usp.br<mailto:leish-l at lineu.icb.usp.br>>
Message-ID:
<CAE-TCmS=i=WaT8cAeOXUJmot=KPvMQSLKar6CTfuUBK9M9tsUw at mail.gmail.com<mailto:CAE-TCmS=i=WaT8cAeOXUJmot=KPvMQSLKar6CTfuUBK9M9tsUw at mail.gmail.com>>
Content-Type: text/plain; charset=windows-1252
10 Aug 2011
Dear Professor Paul Kaye,
Thank you for your email. Please find attached our supportive letter
of interest for Leishmaniasis Pathology Network.
Looking forward for your kind response.
Best regards.
--
*Prof. Dr. Moazzem Hossain *
Ex - Director Disease Control
Ministry of Health & Family Welfare
Government of Bangladesh
*Mailing address*:
Founder Chairman and Project Director
Institute of Allergy & Clinical Immunology of Bangladesh (IACIB)
Room 4 - 5 (2nd Floor), Green Super Market, Green Road
Dhaka -1205, Bangladesh.
Phone:880-2-8115646 (O )
880-1715038551(Mobile)
Email: directordcbd at gmail.com<mailto:directordcbd at gmail.com>
On 8/9/11, jeffrey shaw <jayusp at hotmail.com<mailto:jayusp at hotmail.com>> wrote:
Date: Tue, 9 Aug 2011 11:58:52 +0100
From: paul.kaye at york.ac.uk<mailto:paul.kaye at york.ac.uk>
Subject: Leishmaniasis Pathology Network
Dear all,
Invitation to participate in a global pathology
network for
research and training in leishmaniasis (LeishPathNet)
You may recall the Dormy House meeting in 2008
and some of
the plans we put forward? Over
the past
couple years, I have also spoken more to a few of you about one
idea that was
formulated at Dormy, namely of setting up a digital pathology
network. I have
also had numerous discussions with the major equipment
manufacturers to see if
any of them would be supportive of helping us to develop such an
initiative. There have
been two major
develoments recently. First,
Carl Zeiss
is willing to work with us to set up an integrated global digital
pathology
network (providing a significant financial and technical
contribution) and
second, the Wellcome Trust is willing to review a pre-proposal to
fund the
initiative through their new Biomedical Resources Grant scheme
(http://www.wellcome.ac.uk/Funding/Biomedical-science/Funding-schemes/Strategic-awards-and-initiatives/wtdv031727.htm)
.
I have attached an outline of the project that
I had sent to
the Trust for their initial views, which I think is reasonably
self-explanatory.
They appeared very
enthusiastic! The main
question now is whether enough of
you are still supportive? [ I will also be sending this email to
others, but please feel free to circulate ]
I think the
project will be
challenging, but success could have a real impact on the way we
conduct
business. It should serve not only as a vehicle to enhance
research in
leishmaniasis, but the model would be equally applicable across
a broad range
of diseases and global challenges (with leishmaniasis setting
the pace).
If we wish to
proceed, the requirements
are that we submit a pre-proposal to the Trust by Oct 18th 2011.
This pre-proposal is short (4 sections of 350 words) and
requires
letters of support from the community.
If you are
supportive of the idea that
we try to take this forward (and there is plenty of scope for
later iteration
of the detail), I would be grateful if you could please provide
me with a
letter of support by September
12th
2011, indicating whether you would like to be a network
partner if the bid
is successful. You could
also be
supportive but not wish to become directly involved at this
stage, and such
letters are equally valuable. Your letter might also stress the
added value
that the network could provide, its importance for research and
training and/or
for progressing the translational agenda.
It would also be an opportunity to indicate whether your
group (or
institute, if multiple groups) would be interested in bidding to
be one of the
initial ?designated laboratories?.
If there is
sufficient support to
proceed and if subsequently the pre-proposal is successful (we
will know on 22nd
Nov), then I will need a few volunteers to help finalise the
full proposal,
which will be due on Jan 26th 2012.
A funding decision will be made on May 26th
2012.
Best wishes
and of course I am happy to
discuss any points further (though I will be out of the UK from
Aug 10 ?Sept
12)
Paul
--
Professor Paul Kaye, Ph.D., FRCPath.
Deputy Dean (Research), Hull York Medical School, and
Director, Centre for Immunology and Infection
Department of Biology and Hull York Medical School
University of York
Wentworth Way
York YO10 5YW
United Kingdom
Tel: +44 (0)1904 328840
Fax: +44 (0)1904 328844
Email: paul.kaye at york.ac.uk<mailto:paul.kaye at york.ac.uk> <mailto:paul.kaye at york.ac.uk>
Centre Administrator and PA: Elizabeth Greensted
Tel: 01904 328845
Email: liz.greensted at york.ac.uk<mailto:liz.greensted at york.ac.uk> <mailto:liz.greensted at york.ac.uk>
Centre Email: cii at york.ac.uk<mailto:cii at york.ac.uk> <mailto:cii at york.ac.uk>
Centre website: http://www.york.ac.uk/cii
Times Higher Education University of the Year 2010
Email disclaimer: http://www.york.ac.uk/docs/disclaimer/email.htm
------------------------------
Message: 3
Date: Wed, 10 Aug 2011 13:06:47 +0600
From: Moazzem Hossain <directordcbd at gmail.com<mailto:directordcbd at gmail.com>>
Subject: Re: [Leish-l] FW: Leishmaniasis Pathology Network
To: jeffrey shaw <jayusp at hotmail.com<mailto:jayusp at hotmail.com>>, "Prof. Paul Kaye"
<paul.kaye at york.ac.uk<mailto:paul.kaye at york.ac.uk>>
Cc: "Prof. Dr. Moazzem Hossain" <profdrmoazzemhossain at gmail.com<mailto:profdrmoazzemhossain at gmail.com>>,
Leish-L <leish-l at lineu.icb.usp.br<mailto:leish-l at lineu.icb.usp.br>>
Message-ID:
<CAE-TCmQNUkZdNE5w+Z20bjLC-=vvV9BCP6OLOm9f6RV-BfpXvA at mail.gmail.com<mailto:CAE-TCmQNUkZdNE5w+Z20bjLC-=vvV9BCP6OLOm9f6RV-BfpXvA at mail.gmail.com>>
Content-Type: text/plain; charset="windows-1252"
10 Aug 2011
Dear Professor Paul Kaye,
Thank you for your email. Please find attached our supportive letter
of interest for Leishmaniasis Pathology Network.
Looking forward for your kind response.
Best regards.
--
*Prof. Dr. Moazzem Hossain *
Ex - Director Disease Control
Ministry of Health & Family Welfare
Government of Bangladesh
*Mailing address*:
Founder Chairman and Project Director
Institute of Allergy & Clinical Immunology of Bangladesh (IACIB)
Room 4 - 5 (2nd Floor), Green Super Market, Green Road
Dhaka -1205, Bangladesh.
Phone:880-2-8115646 (O )
880-1715038551(Mobile)
Email: directordcbd at gmail.com<mailto:directordcbd at gmail.com>
On 8/9/11, jeffrey shaw <jayusp at hotmail.com<mailto:jayusp at hotmail.com>> wrote:
Date: Tue, 9 Aug 2011 11:58:52 +0100
From: paul.kaye at york.ac.uk<mailto:paul.kaye at york.ac.uk>
Subject: Leishmaniasis Pathology Network
Dear all,
Invitation to participate in a global pathology
network for
research and training in leishmaniasis (LeishPathNet)
You may recall the Dormy House meeting in 2008
and some of
the plans we put forward? Over
the past
couple years, I have also spoken more to a few of you about one
idea that was
formulated at Dormy, namely of setting up a digital pathology
network. I have
also had numerous discussions with the major equipment
manufacturers to see if
any of them would be supportive of helping us to develop such an
initiative. There have
been two major
develoments recently. First,
Carl Zeiss
is willing to work with us to set up an integrated global digital
pathology
network (providing a significant financial and technical
contribution) and
second, the Wellcome Trust is willing to review a pre-proposal to
fund the
initiative through their new Biomedical Resources Grant scheme
(http://www.wellcome.ac.uk/Funding/Biomedical-science/Funding-schemes/Strategic-awards-and-initiatives/wtdv031727.htm)
.
I have attached an outline of the project that
I had sent to
the Trust for their initial views, which I think is reasonably
self-explanatory.
They appeared very
enthusiastic! The main
question now is whether enough of
you are still supportive? [ I will also be sending this email to
others, but please feel free to circulate ]
I think the
project will be
challenging, but success could have a real impact on the way we
conduct
business. It should serve not only as a vehicle to enhance
research in
leishmaniasis, but the model would be equally applicable across
a broad range
of diseases and global challenges (with leishmaniasis setting
the pace).
If we wish to
proceed, the requirements
are that we submit a pre-proposal to the Trust by Oct 18th 2011.
This pre-proposal is short (4 sections of 350 words) and
requires
letters of support from the community.
If you are
supportive of the idea that
we try to take this forward (and there is plenty of scope for
later iteration
of the detail), I would be grateful if you could please provide
me with a
letter of support by September
12th
2011, indicating whether you would like to be a network
partner if the bid
is successful. You could
also be
supportive but not wish to become directly involved at this
stage, and such
letters are equally valuable. Your letter might also stress the
added value
that the network could provide, its importance for research and
training and/or
for progressing the translational agenda.
It would also be an opportunity to indicate whether your
group (or
institute, if multiple groups) would be interested in bidding to
be one of the
initial ?designated laboratories?.
If there is
sufficient support to
proceed and if subsequently the pre-proposal is successful (we
will know on 22nd
Nov), then I will need a few volunteers to help finalise the
full proposal,
which will be due on Jan 26th 2012.
A funding decision will be made on May 26th
2012.
Best wishes
and of course I am happy to
discuss any points further (though I will be out of the UK from
Aug 10 ?Sept
12)
Paul
--
Professor Paul Kaye, Ph.D., FRCPath.
Deputy Dean (Research), Hull York Medical School, and
Director, Centre for Immunology and Infection
Department of Biology and Hull York Medical School
University of York
Wentworth Way
York YO10 5YW
United Kingdom
Tel: +44 (0)1904 328840
Fax: +44 (0)1904 328844
Email: paul.kaye at york.ac.uk<mailto:paul.kaye at york.ac.uk> <mailto:paul.kaye at york.ac.uk>
Centre Administrator and PA: Elizabeth Greensted
Tel: 01904 328845
Email: liz.greensted at york.ac.uk<mailto:liz.greensted at york.ac.uk> <mailto:liz.greensted at york.ac.uk>
Centre Email: cii at york.ac.uk<mailto:cii at york.ac.uk> <mailto:cii at york.ac.uk>
Centre website: http://www.york.ac.uk/cii
Times Higher Education University of the Year 2010
Email disclaimer: http://www.york.ac.uk/docs/disclaimer/email.htm
-------------- next part --------------
A non-text attachment was scrubbed...
Name: Letter Leish UK.doc
Type: application/msword
Size: 46080 bytes
Desc: not available
URL: <http://lineu.icb.usp.br/pipermail/leish-l/attachments/20110810/73f2ae6a/attachment.doc>
------------------------------
_______________________________________________
Leish-l mailing list
Leish-l at lineu.icb.usp.br<mailto:Leish-l at lineu.icb.usp.br>
http://lineu.icb.usp.br/cgi-bin/mailman/listinfo/leish-l
End of Leish-l Digest, Vol 44, Issue 3
**************************************
=======
Email scanned by PC Tools - No viruses or spyware found.
(Email Guard: 7.0.0.26, Virus/Spyware Database: 6.18330)
http://www.pctools.com/
=======
_______________________________________________
Leish-l mailing list
Leish-l at lineu.icb.usp.br<mailto:Leish-l at lineu.icb.usp.br>
http://lineu.icb.usp.br/cgi-bin/mailman/listinfo/leish-l
-------------- next part --------------
An HTML attachment was scrubbed...
URL: <http://lineu.icb.usp.br/pipermail/leish-l/attachments/20110928/0d74fb44/attachment-0001.htm>
-------------- next part --------------
A non-text attachment was scrubbed...
Name: image001.gif
Type: image/gif
Size: 26494 bytes
Desc: image001.gif
URL: <http://lineu.icb.usp.br/pipermail/leish-l/attachments/20110928/0d74fb44/attachment-0001.gif>
More information about the Leish-l
mailing list